Fatty Acid Synthesis

Overview

Fatty acid synthesis (lipogenesis) is the anabolic pathway by which cells build long-chain fatty acids from the two-carbon precursor acetyl-CoA. This process occurs primarily in the liver and adipose tissue and is the biochemical basis for converting excess dietary carbohydrates into fat for long-term energy storage. Fatty acid synthesis is tightly regulated by hormonal signals — most notably insulin — and its dysregulation is central to obesity, metabolic syndrome, and non-alcoholic fatty liver disease (NAFLD).

For the peptide field, fatty acid synthesis is relevant because many metabolic peptide therapeutics — including semaglutide, tirzepatide, and MOTS-c — exert part of their anti-obesity and insulin-sensitizing effects by modulating lipogenic pathways. Additionally, fatty acid acylation is a key pharmaceutical strategy: the attachment of fatty acid chains to peptides (as in semaglutide's C18 fatty acid) extends their half-life by promoting albumin binding.

The Pathway

Acetyl-CoA Production and Export

The substrate for fatty acid synthesis is acetyl-CoA, produced in the mitochondrial matrix from glycolysis-derived pyruvate (via pyruvate dehydrogenase), amino acid catabolism, and fatty acid beta-oxidation. Since fatty acid synthesis occurs in the cytoplasm and the inner mitochondrial membrane is impermeable to acetyl-CoA, a shuttle system is required: acetyl-CoA condenses with oxaloacetate to form citrate, which is exported to the cytoplasm by the citrate transporter and then cleaved back to acetyl-CoA and oxaloacetate by ATP-citrate lyase.

Acetyl-CoA Carboxylase (ACC)

The committed and rate-limiting step of fatty acid synthesis is the carboxylation of acetyl-CoA to malonyl-CoA, catalyzed by acetyl-CoA carboxylase (ACC). This biotin-dependent enzyme exists in two isoforms: ACC1 (cytoplasmic, drives lipogenesis) and ACC2 (associated with the outer mitochondrial membrane, regulates beta-oxidation). ACC is the primary regulatory point of the pathway and a major target of metabolic regulation.

Fatty Acid Synthase (FAS)

Fatty acid synthase is a large multifunctional enzyme that catalyzes the cyclic addition of two-carbon units from malonyl-CoA to a growing fatty acid chain. Each cycle adds two carbons, reduces the intermediates using NADPH, and releases water. After seven cycles of elongation, the product is palmitate (16:0), a saturated 16-carbon fatty acid. Further elongation and desaturation occur in the endoplasmic reticulum to produce the full diversity of cellular fatty acids.

Regulation

Insulin — The Master Lipogenic Signal

Insulin is the primary hormonal activator of fatty acid synthesis. In the fed state, insulin stimulates lipogenesis through multiple mechanisms:

• Activates ACC by promoting its dephosphorylation
• Upregulates transcription of ACC, FAS, and ATP-citrate lyase through the transcription factor SREBP-1c
• Stimulates glucose uptake and glycolysis, increasing acetyl-CoA supply
• Inhibits lipolysis in adipose tissue, reducing fatty acid release

Insulin resistance — the hallmark of type 2 diabetes and metabolic syndrome — paradoxically coexists with continued hepatic lipogenesis, contributing to NAFLD. This selective insulin resistance (impaired glucose regulation but preserved lipogenic signaling) is a major area of metabolic research.

AMPK — The Lipogenic Brake

AMPK phosphorylates and inactivates ACC, shutting down fatty acid synthesis when cellular energy is low. This is one of the key mechanisms by which exercise, caloric restriction, and MOTS-c reduce lipogenesis. Metformin, the most widely prescribed diabetes drug, activates AMPK and thereby inhibits hepatic lipogenesis.

Glucagon

Glucagon, the counter-regulatory hormone to insulin, inhibits fatty acid synthesis by activating AMPK (via cAMP-PKA signaling) and promoting fatty acid oxidation instead.

mTOR

The mTOR pathway promotes lipogenesis by activating SREBP-1c transcription. Nutrient sensing through mTOR integrates amino acid availability with lipid synthesis.

Connections to Peptide Therapeutics

GLP-1 Receptor Agonists

Semaglutide, liraglutide, tirzepatide, and other GLP-1 receptor agonists reduce hepatic lipogenesis through multiple mechanisms: improving insulin sensitivity, reducing hyperinsulinemia, decreasing caloric intake, and potentially through direct hepatic effects. Clinical trials have demonstrated significant reductions in liver fat content with these agents, and they are being investigated for NAFLD/NASH treatment.

MOTS-c

MOTS-c activates AMPK, which directly phosphorylates and inactivates ACC, suppressing fatty acid synthesis. This is one mechanism by which MOTS-c improves metabolic health in preclinical models.

Fatty Acid Acylation in Drug Design

The attachment of fatty acid chains to peptides is a widely used strategy to extend their duration of action. Semaglutide contains a C18 fatty diacid linker that binds albumin in the blood, protecting the peptide from degradation and renal filtration. Liraglutide uses a C16 fatty acid for the same purpose. This pharmaceutical application of fatty acids demonstrates how understanding lipid biochemistry directly informs peptide drug design.

Clinical Relevance

Dysregulated fatty acid synthesis contributes to several conditions relevant to peptide therapy:

• Obesity — Excess lipogenesis from dietary carbohydrate overconsumption drives fat accumulation. See Peptides in Obesity Treatment.
• NAFLD/NASH — Hepatic de novo lipogenesis is elevated in these conditions, contributing to steatosis, inflammation, and fibrosis.
• Metabolic syndrome — The combination of insulin resistance, dyslipidemia, and visceral obesity reflects dysregulated lipid metabolism. See Metabolic Syndrome Protocol.
• Cancer — Many tumors upregulate fatty acid synthesis (via FAS overexpression) to support rapid membrane biogenesis.

See Also

• Insulin — The primary hormonal regulator of lipogenesis
• AMPK Pathway — The energy sensor that inhibits fatty acid synthesis
• Cholesterol Metabolism — A related lipid biosynthetic pathway
• Semaglutide — A fatty acid-acylated peptide therapeutic
• Peptides in Obesity Treatment — Therapeutic applications